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Turner syndrome (TS) and related sex chromosome
abnormalities are associated with a variety of karyo-
types and phenotypes affecting 1 in 2500 live births.
Mosaicism with Y material (45,X/46,XY) and female
phenotype is rare (<1 in 15 000 births)[1]. Their risk
of gonadal malignancy is 10-15%, and up to 50% in
those with ambiguous phenotype at birth[2]. The
SHOX gene is located on both X and Y chromosomes
but is more prone to deletions on the X chromosome,
potentially influencing height outcomes across TS kar-
yotypes[3]. However, children with SHOX deficiency
respond similarly to TS girls when treated with the
same dose of growth hormone (GH)[4]. We therefore
examined height outcomes and gonadal malignancy
rates in TS vs 45,X/46,XY females.
We identified 198 females aged ≤ 30 years with TS
or mixed gonadal dysgenesis treated with GH (under
TS or auxological criteria). Final height (FH) was avail-
able on 51 TS (45,X or mosaic without Y material)
females. An additional 13 had 45,X/46,XY karyotype
with TS phenotype, and two had non-mosaic 46,XY
karyotypes with cytogenetic abnormalities consistent
with TS. Of these 15 females, gonadal tissue histology
was available for 11 and FH in nine. We evaluated
patient records for age, height, mid-parental height
(MPH), GH dose at commencement, duration of ther-
apy and growth response at 12 months and at FH.
Comparisons between TS and 45,X/46,XY groups were
performed using the Mann-Whitney U test.
All 45,X/46,XY patients had a female phenotype and
five had clitoromegaly at birth. Three were identified
prenatally; age at diagnosis ranged from birth to 13
years, with the most common presenting features being
short stature (n=5), ambiguous genitalia (n=5) and
dysmorphic features (n=2). Of the 11 that underwent
gonadectomy, four (none virilised at birth) had a gona-
doblastoma, including one dysgerminoma in situ.
Age, height, MPH,GH dose at commencement, dura-
tion of therapy and height z-score after 12 months did
not differ between groups. Median FH z-score for 45,X/
46,XY was higher than TS, -1.12 [range -1.96,0.31], vs
-1.59 [-3.12,0.01], p=0.016. Response to GH therapy
(median Δ height z-score) after 12 months was similar:
0.45 [-0.04,0.84] vs 0.39 [-0.21,1.14], p=0.81. However,
height response over the total duration of therapy was
better for 45,X/46XY: 1.5 [0.72,2.88] vs 0.87 [-0.98,2.14],
p=0.009.
45,X/46,XY females appear to respond differently to
GH therapy, suggesting a possible contribution of
SHOX on the Y chromosome. The rate of germ cell
tumours in non-virilised females (36%) is higher than
previously reported.
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